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INTRODUCTION
Transient receptor vanilloid 1 (TRPV1) is a member of the 
transient receptor potential (TRP) family that is expressed in 
several neural and nonneuronal tissues of different animal 
species [1]. It is a Ca2+-permeable nonselective cation channel 
that can be activated by noxious heat (> 43°C), low pH (< 6), 
and various lipophilic compounds, including capsaicin and 
phopholipid derivatives [2]. TRPV1 is composed of six trans-
membrane spanning domains (S1–S6), intracellular N and C 
termini, and a pore-forming hydrophobic stretch between the 
fifth and the sixth domains [3].
Physiologically, TRPV1 is expressed in dorsal root, trigemi-
nal, and nodose ganglion neurons that are associated with no-
ciceptive afferents, enabling detection and integration of nox-
ious stimuli [4] in different organs, such us the bladder [4], 
kidneys [5], brain [6], and lungs [7,8]. Moreover, there are 
strong indications that TRPV1 is involved in many pathologi-
cal conditions, including abnormalities in pain sensation, epi-
lepsy, osteoarthritis, pancreatitis, asthma, and non-insulin- 
dependent diabetes mellitus [9]. In the last decade, TRPV1 
has also been identified in humans in neoplastic tissues such 
as squamous cell carcinoma of the tongue [10], prostate carci-
noma [11], colon cancer [9], transitional urothelial cancer of 
the bladder [12], and breast cancer [9]. 
Based on this information, calcium is considered an impor-
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Purpose: Transient receptor potential vanilloid 1 (TRPV1) is a non-
selective cation channel belonging to the transient receptor po-
tential family, and it is expressed in different neoplastic tissues. 
Its activation is associated with regulation of cancer growth and 
progression. The aim of this research was to study the expres-
sion and pharmacological characteristics of TRPV1 in cells de-
rived from human breast cancer MCF-7 cells. Methods: TRPV1 
presence was assessed by binding studies and Western blotting. 
Receptor binding characteristics were evaluated through com-
petition assays, while 3-(4,5-dimethylthiazol-2-yl)-2,5,-dipheyltet-
razolium bromide reduction assays were performed to confirm 
an early hypothesis regarding the modulation of cancer cell pro-
liferation. The functionality of TRPV1 was evaluated by measur-
ing Ca2+ uptake in the presence of increasing concentrations of 
TRPV1 agonists and antagonists. Results: Binding studies identi-
fied a single class of TRPV1 (Bmax 1,492±192 fmol/mg protein), 
and Western blot showed a signal at 100 kDa corresponding to 
the molecular weight of human TRPV1. Among the different test-
ed agonists and antagonists, anandamide (Ki: 2.8×10-11 M) and 
5-iodoresiniferatoxin (5-I-RTX) (Ki: 5.6×10-11 M) showed the high-
est degrees of affinity for TRPV1, respectively. All tested TRPV1 
agonists and antagonists caused a significant (p<0.05) decrease 
in cell growth rate in MCF-7 cells. For agonists and antagonists, 
the efficacy of tested compounds displayed the following rank 
order: resiniferatoxin>anandamide>capsaicin and 5-I-RTX= 
capsazepine, respectively. Conclusion: These data indicate that 
both TRPV1 agonists and antagonists induce significant inhibi-
tion of MCF-7 cell growth. Even though the mechanisms in-
volved in the antiproliferative effects of TRPV1 agonists and an-
tagonists should be further investigated, it has been suggested 
that agonists cause desensitization of the receptor, leading to al-
teration in Ca2+-influx regulation. By contrast, antagonists cause 
a functional block of the receptor with consequent fatal dysregu-
lation of cell homeostasis.
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tant intracellular messenger that regulates physiological func-
tions, including cellular differentiation, proliferation, and 
apoptosis. Additionally, it has been suggested that TRPV chan-
nels are involved in cancer growth and progression [13]. San-
toni et al. [12] found, for example, that TRPV1 expression de-
creases during the development of transitional cell carcinoma 
of the human bladder, outlined its key role in the regulation of 
tumor cell proliferation, and even discussed the possibility of 
its use as a possible therapeutic target [7].
Breast cancer is a leading cause of death globally. Recent ep-
idemiological data suggest that in 2008, almost 1.4 million 
women worldwide were diagnosed with breast cancer and ap-
proximately 459,000 deaths were recorded. The 5-year relative 
survival rate ranges from 12% to 90% depending on the diag-
nostic and therapeutic approaches used [14]. Traditional phar-
macological treatments cause severe side effects; therefore, it is 
important to identify new targets to improve the clinical out-
come of these patients [12].
Accordingly, the aim of this study was to identify and char-
acterize TRPV1 in cells derived from human breast adenocar-
cinoma and study the modulation of cancer cell proliferation 
induced by different specific TRPV1 agonists and antagonists. 
METHODS
Cell culture 
MCF-7 cells (cells derived from pleural effusion after pleu-
ral methastatisation of human breast adenocarcinoma) 
(ATCC Cell Culture-LGC Standards, Milan, Italy) were cul-
tured in 75 mL flasks containing Dulbecco’s Modified Eagles 
Medium (DMEM; Lonza, Basel, Switzerland), 20% fetal bo-
vine serum (FBS; Sigma Aldrich, Milan, Italy), 2% L-gluta-
mine (Lonza), and 2% penicillin-streptomicin-amphotericin 
B solution (Sigma Aldrich) at 37°C with 5% CO2, 95% air, and 
complete humidity. When a confluence of 80% was reached, 
cells were detached using 0.1% trypsin/EDTA solution (Sigma 
Aldrich), centrifuged, and counted using Trypan Blue solu-
tion (Sigma Aldrich) with a Burker chamber. Cells were either 
resuspended at a concentration of 5× 105 cells/mL or stored at 
-80°C for further analysis.
Radioligand binding assays 
Cell membrane suspensions obtained by fractioned ultra-
centrifugation were diluted to a final concentration of 1 mg 
protein/mL, and 100 μL aliquots were incubated for 1 hour at 
37°C in a shaking water bath with increasing concentrations 
(0.025–3.2 nM) of labeled resiniferatoxin (RTX) (3[H]RTX 43 
Ci/mmol; PerkinElmer, Boston, USA) in the absence (total 
binding) and in the presence (nonspecific binding) of 1 μM 
unlabelled RTX. After stopping the incubation, the mixture 
was filtered under vacuum using presoaked glass fiber filters 
(Whatmann GF/B; Whatmann, Maidstone, UK). Filters were 
carefully washed with buffered saline solution (154 mM NaCl, 
50 mM tris HCl, pH 7.4; Sigma Aldrich) and solubilized with 
4 mL of scintillation fluid (Filter Count; Canberra Packard, 
Meridien, USA). The radioactivity retained on wet filters was 
measured for 2 minutes using a Tri-Carb 1600 TR Canberra 
Packard scintillator spectrometer (Canberra Packard) at an ef-
ficiency of 60%.
The equilibrium dissociation constant (Kd), expressed as nM, 
and the maximum number of binding sites (Bmax), expressed as 
fmol of specifically bound labeled ligand per milligram of 
membrane proteins, were determined (n = 8) by Scatchard 
analysis [15] using GraphPad Prism Software (GraphPad Soft-
ware, San Diego, USA).
Western blotting assay 
To confirm the presence of TRPV1 in MCF-7, cell mem-
brane suspensions were mixed with Laemmli buffer (5×  solu-
tion: 3 mL 1 M Tris-HCl pH 6.8, 5 mL glicerol, 1.5 g sodium 
dodecyl sulfate [SDS], 50 mg bromophenol blue, and 320 µL 
β-mercaptoethanol [Sigma Aldrich]), diluted at 1×  by adding 
phosphate buffered saline (PBS) and boiled for 5 minutes. A 
gel with 8% of acrilamide was used for SDS-PAGE procedure 
(Biosolve, Valkenswaard, The Netherlands). A lysate of uri-
nary rat bladder was used as a positive control [4].
The samples were transferred to nitrocellulose membranes 
(Hybond ECL; Amersham, GE Healthcare, Milan, Italy) and 
dyed with Red Ponceau (Sigma Aldrich). After being washed 
three times, samples were probed with the primary anti-
TRPV1 antibody (goat polyclonal antibody; Santa Cruz Bio-
technology Inc., Heidelberg, Germany) (dilution 1:100) and 
incubated overnight at 5°C on a shaking plate. At the end of 
the incubation period, samples were washed again and probed 
with secondary antibody (donkey antigoat IgG-HRP; Santa 
Cruz Biotechnology Inc.) (dilution 1:15,000) for 1 hour. The 
immunoreactive bands were visualized by enhanced chemilu-
minescence (ECL-Plus System; Amersham, GE Healthcare).
Functional studies
For the 45Ca2+ uptake assay, 250 μL of cell suspension (5×  
103/100 μL) was incubated for 20 minutes at 37°C in a shaking 
bath in the presence of 1 μCi 45Ca2+/mL (45Ca 27.63 mCi/mL; 
PerkinElmer) in parallel sets of tubes with increasing concen-
trations (10-11–10-3 M) of selective agonists (RTX, capsaicin, 
and anandamide; Sigma Aldrich) and antagonists (5-io-
doresiniferatoxin [5-I-RTX] and capsazepine; Sigma Aldrich). 
Immediately after incubation, 45Ca2+ was removed by washing 
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with ice-cold PBS (140 mM NaCl, 27 mM KCl, 15 mM KH2 
PO4, 90mM Na2HPO4, pH= 7.4; Sigma Aldrich). Then, 3 mL 
of scintillation fluid (Ultima Gold; Canberra Packard) was 
added to the cell suspensions, and radioactivity (cpm/well) 
was measured by a scintillator spectrometer. The molar con-
centration of agonists producing 50% of the maximum possi-
ble response (EC50) and antagonist inhibitory concentration 
50 (IC50) were then calculated [16].
Competition assays
Receptor binding characteristics were studied by displace-
ment assays using TRPV1 selective agonists (capsaicin, anan-
damide, and RTX; Sigma Aldrich) and antagonists (capsaze-
pine, 5-I-RTX, and SB-366791; Sigma Aldrich). Aliquots of 
100 µL of membrane suspension (1 mg protein/mL) were in-
cubated with increasing concentrations (10-10–10-3 M) of the 
TRPV1 unlabelled agonists and antagonists in presence of 1.2 
nM 3[H]RTX. The concentration of unlabelled ligand that it 
took to inhibit 50% (IC50) of 3[H]RTX specific binding was de-
termined from the competition curves obtained by nonlinear 
regression analysis of the data (GraphPad Prism; GraphPad 
Software). The fit of the one-site model was tested by R2 by 
nonlinear regression and by the runs test. The affinity constant 
(Ki) for the competitors were calculated using the Cheng-
Prussoff equation [17].
Proliferation assay
The MTT (Sigma Aldrich) reduction assay, a routine method 
for quantitating cell viability, was used [18]. Cells (5 × 103 
cells/100 µL) were transferred into 96-well plates in order to 
perform the MTT assay at 24, 48, and 72 hours after seeding. 
After an overnight incubation at 37°C and 5% CO2, the medi-
um was changed (DMEM, FBS 5%, antibiotic and antimycotic 
solution 2%, L-glutamine 2%), and increasing concentrations of 
agonists (capsaicin [10-10–10-4 M] and RTX [10-10–10-6 M]) and 
antagonists (capsazepine [10-10–10-4 M] and 5-I-RTX [10-10– 
10-6 M]) were added.
After adding MTT (Sigma Aldrich) solution, the plates 
were incubated at 37°C and 5% CO2 for 4 hours. At the end of 
incubation, the medium was removed, and 100 µL of dimeth-
yl sulfoxide (DMSO; Sigma Aldrich) was added in order to ly-
sate the formazan crystals. The plates were further incubated 
for 10 minutes at room temperature, and the optical density of 
the wells was determined using a plate reader (Poverwave x; 
Bio-Tek Instruments Inc., Winooski, USA) at a wavelength of 
570 nm [19]. The results, expressed as mean± SEM, were ana-
lyzed using GraphPad Prism Software as well as applying the 
Kruskal-Wallis test and a Dunn post-test. Significant values 
were considered p< 0.05.
RESULTS
Binding assay
Scatchard analysis identified a single class of TRPV1 char-
acterized by high affinity for 3[H]RTX (Figure 1). The Bmax 
value was 1,492± 192 fmol/mg of protein (mean± SEM) and 
the Kd value was 0.03± 0.004 nM (mean± SEM, r> 0.9).
Western blotting assays
Figure 2 shows a signal corresponding to a molecular weight 
of about 100 kDa, which is consistent with that reported for 
human TRPV1 [20]. The same signal was observed in rat uri-
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Figure 1. Scatchard plot (A) and saturation curve of MCF-7 binding membranes (B). One hundred microliters of cell membrane suspension were in-
cubated with increasing concentration (0.025–3.2 nM) of 3[H]RTX and in presence or in absence of 1 μM unlabelled RTX. The specific bound labeled 
ligand was determined by Scatchard analysis using GraphPad Prism Software (GraphPad Software) (n=8). 
RTX=resiniferatoxin.
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nary bladder lysate, which was used as a positive control.
Functional studies
Figure 3 shows dose-response curves describing Ca2+ up-
take induced by increasing concentrations of RTX, capsaicin, 
and anandamide. The efficacy of tested compounds displayed 
the following rank order: RTX (EC50 = 2.4× 10-8 M, R2 > 0.9, E 
max = 777.0 cpm) > anandamide (EC50 = 1.10 × 10-7 M, R2 >  
0.9, E max = 557.0 cpm) > capsaicin (EC50 = 1.52 × 10-7 M, 
R2 > 0.9, E max= 478.8 cpm). Figure 4 shows the percentage of 
Ca2+ influx inhibition induced by increasing concentrations of 
the two tested antagonists 5-I-RTX and capsazepine. The IC50 
for 5-I-RTX and capsazepine were 5.6 × 10-11 M, R2 > 0.9, 
E max= 108.3% and 7.9× 10-11 M, R2 > 0.9, E max= 104.0%, 
respectively. All significant differences were observed between 
antagonists.
Competition assays 
The results obtained by competition assays are shown in Ta-
bles 1 and 2. The Ki values demonstrate that tested agonists dis-
placed the radioligand from its specific binding sites in the fol-
lowing order of potency: anandamide> capsaicin> RTX. For the 
antagonists, the order of potency was 5-I-RTX> capsazepine>  
SB-366791.
Proliferation assay
Results concerning the effects induced by different concen-
trations of capsaicin, capsazepine, RTX, and 5-I-RTX on 
MCF-7 viability are represented in Figures 5–8. All agonists 
and antagonists caused a significant decrease (p < 0.05) in 
treated cell viability compared with controls. Moreover, RTX 
(Figure 7) was the only compound to show time-dependent 
behavior.
TRPV1
100 µg50 µg25 µgK+
Figure 2. The samples used for Western blot analysis were at different 
concentrations: 25, 50, and 100 µg of protein. The image shows a sig-
nal corresponding to the molecular weight around 100 kDa that is re-
ported to correspond to transient receptor potential vanilloid 1 (TRPV1) 
receptor. The signal was also present in the positive control (first column, 
K+), composed by proteic lysate of rat urinary bladder. 
Figure 3. During functional studies, the stimulation of 45Ca2+ uptake in 
MCF-7 membranes was induced by adding increasing concentrations 
(10-11–10-3) of selective agonists: anandamide, resiniferatoxin (RTX), and 
capsaicin. For each data point in each experiment, four wells were as-
sayed (n=4). The error bars indicate SEM (GraphPad Prism Software; 
GraphPad Software). 
Figure 4. Inhibition of resiniferatoxin (RTX) induced 45Ca2+ uptake by two 
selective transient receptor potential vanilloid 1 antagonists (5-iodoresin-
iferatoxin [5-I-RTX] and capsazepine) in MCF-7 cell membranes. For 
each data point in each experiment, four wells were assayed (n=4). The 
error bars indicate SEM (GraphPad Prism Software; GraphPad Soft-
ware). The antagonists have been tested in the presence of RTX 2 nM 
for the measurement of the percentage of inhibition of 45Ca2+ uptake 
(IC50) (GraphPad Prism Software). 
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Table 1. Inhibition of 3[H]RTX binding to transient receptor potential 
vanilloid 1 by selected agonists
Ki (M) R2 E max (%)
Anandamide 2.8×10-11 >0.9 92.01
Capsaicin 1.6×10-10 >0.9 102.20
RTX 1.3×10-8 >0.9 82.40
Competition assays using antagonists compounds.
Ki=affinity constant; E max=efficacy; RTX=resiniferatoxin.
Table 2. The affinities (Ki) for the different selective transient receptor 
potential vanilloid 1 antagonists
Ki (M) R2 E max (%)
5-I-RTX 5.6×10-11 >0.9 94.97
Capsazepine 7.9×10-11 >0.9 93.00
SB-366791 7.5×10-10 >0.9 95.11
Competition assays using antagonists compounds.
Ki=affinity constant; E max=efficacy; 5-I-RTX=5-iodoresiniferatoxin.
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DISCUSSION
Although the importance of TRP channels in different solid 
tumors has been recently outlined, their role in breast cancer 
has been insufficiently investigated. In this study, we demon-
strated the presence of TRPV1 in MCF-7 cells by means of 
two different techniques (binding assays and Western blot-
ting). Binding assays revealed the presence of measurable and 
saturable concentrations of TRPV1. The apparent molecular 
weight of the protein detected by Western blot is consistent 
with that described in other cell types [19]. The presence and 
functionality of TRPV1 in breast cancer cell lines had already 
Figure 5. MTT assay (n=6) to evaluate the modulation of MCF-7 cells 
growth after the treatment with increasing concentration (10-10–10-4 M) 
of capsaicin at different experimental time points (2, 24, 48, and 72 
hours). All the samples treated with increasing concentrations of capsa-
icin demonstrated a significant decrease (p<0.05) of the cell growth rate 
compared to the controls (K). The MCF-7 cells proliferation was statisti-
cally analyzed using Kruskal-Wallis test and Dunn post-test (mean± 
SEM).
OD=optical density; a, b, c, d= p<0.05. *p<0.05.
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Figure 6. MTT assay (n=6) to evaluate the modulation of MCF-7 cells 
growth after the treatment with increasing concentration (10-10–10-4 M) 
of capsazepine at different experimental time points (2, 24, 48, and 72 
hours). All the samples treated with increasing concentrations of cap-
sazepine demonstrated a significant decrease (p<0.05) of the cell 
growth rate compared to the controls (K). The MCF-7 cells proliferation 
was statistically analyzed using Kruskal-Wallis test and Dunn post-test 
(mean±SEM).
OD=optical density; a, b, c, d= p<0.05. *p<0.05.
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Figure 7. MTT assay (n=6) to evaluate the modulation of MCF-7 cells 
growth after the treatment with increasing concentration (10-10–10-6 M) 
of resiniferatoxin (RTX) at different experimental time points (2, 24, 48, 
and 72 hours). All the samples treated with increasing concentrations of 
RTX demonstrated a significant decrease (p<0.05) of the cell growth 
rate compared to the controls (K). The MCF-7 cells proliferation was 
statistically analyzed using Kruskal-Wallis test and Dunn post-test 
(mean±SEM).
OD=optical density; a, b, c, d= p<0.05. *p<0.05.
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Figure 8. MTT assay (n=6) to evaluate the modulation of MCF-7 cells 
growth after the treatment with increasing concentration (10-10–10-6 M) 
of 5-iodoresiniferatoxin (5-I-RTX) at different experimental time points (2, 
24, 48, and 72 hours). All the samples treated with increasing concen-
trations of 5-I-RTX demonstrated a significant decrease (p<0.05) of the 
cell growth rate compared to the controls (K). The MCF-7 cells prolifera-
tion was statistically analyzed using Kruskal-Wallis test and Dunn post-
test (mean±SEM).
OD=optical density; a, b, c, d= p<0.05. *p<0.05.
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been studied, and it was suggested that TRPV1 could repre-
sent a promising therapeutic target for antineoplastic strate-
gies [21]. Other researchers took into consideration the ex-
pression of different TRP channels in human breast ductal 
adenocarcinoma, human breast cancer epithelial primary cul-
ture, and the MCF-7 cell line; their results underscored the 
importance of the role of TRPV6 in neoplastic cell invasion 
and migration [22].
In our study, competition assays indicated that, among ago-
nists and antagonists, anandamide and 5-I-RTX bind with the 
highest affinity to TRPV1. This finding is somewhat consistent 
with the results found by Rigoni et al. [23], who found that 
5-I-RTX, a halogenated version of RTX, has no agonist activity 
but retains nearly the same potency as RTX, was 20 times 
more potent than the antagonist capsazepine.
TRPV1 receptors expressed in MCF-7 were functionally act-
ive, as all of the vanilloid TRPV1 receptor agonists (anan-
damide, RTX, and capsaicin) induced a dose-dependent in-
crease in intracellular calcium concentration that was abol-
ished by the vanilloid TRPV1 receptor antagonists capsaze-
pine and 5-I-RTX. These results are consistent with those ob-
tained in prostate cancer cells [19]. 
When considering calcium uptake, anandamide and capsa-
icin showed similar potency in activating TRPV1, whereas 
RTX was the most potent among tested agonists. Although it 
has been suggested that significant differences emerge when 
comparing the efficacy of anandamide in native and recombi-
nant receptor systems and between tissues, according to our 
results, the compound appears to be a full agonist of TRPV1 
that is expressed in MCF-7, as demonstrated by its E max val-
ue [24]. Similarly, RTX, besides showing a lower degree of af-
finity than anandamide, has proven to be the most potent 
TRPV1 agonist.
Our results also indicate that the number of viable cells, as 
measured by the MTT assay, significantly decreases after ex-
posure to RTX, capsaicin, capsazepine, and 5-I-RTX. It has 
been suggested that receptor-mediated antitumor activity is 
associated with induction of apoptosis following activation of 
TRPV1 and changes in cell calcium influx [21]. Calcium is an 
important intracellular messenger that regulates many physi-
ological functions, such as cellular differentiation, prolifera-
tion, and apoptosis. Abnormal functioning of calcium signal-
ing pathways may occur during carcinogenesis. It has been 
shown, for example, that anandamide induces apoptosis of 
cervical carcinoma cells [25].
On the other hand, there is evidence that changes in TRPV1 
expression may occur in different neoplastic diseases, such as 
prostatic, colonic, pancreatic, and bladder cancers, as previous-
ly mentioned. Kalogris et al. [26] found that TRPV1 is down-
regulated in urothelial cancer specimens, and the decrease in 
TRPV1 mRNA expression correlates with tumor progression. 
It has also been observed that prolonged exposure to agonists 
causes desensitization of TRPV1 by promoting cell surface re-
ceptor internalization with a clathrin-independent pathway 
[27]. Therefore, we cannot exclude the possibility that the in-
hibitory effects on cell viability caused by TRPV1 ligands in 
our study may be due to receptor desensitization.
RTX was the only compound able to induce time-depen-
dent inhibition of MCF-7 cell growth rate and the most effica-
cious among tested agonists. The high efficiency of RTX is the 
reason why this compound has been extensively studied as a 
TRPV1-targeting therapeutic drug in different pathological 
conditions such as bone cancer pain [28]. It has been demon-
strated that RTX causes inhibition of mitochondrial function 
and induces apoptosis in pancreatic cancer cells, presumably 
via endogenous TRPV1 channels, suggesting the use of vanil-
loids to treat pancreatic cancer [29].
According to our results, TRPV1 antagonists caused the 
same inhibitory effect on MCF-7 viability as agonists. The in-
hibitory effect on cell viability induced by specific TRPV1 an-
tagonists could be ascribed to a functional block of the recep-
tor and, consequently, to a modification of cell activities regu-
lated by TRPV1. Furthermore, it has been recently demon-
strated that capsazepine sensitizes colorectal cancer cells to 
apoptosis by decreasing the expression of antiapoptotic pro-
teins (e.g., survivin) and increasing the expression of proapop-
totic proteins (e.g., p53) [30].
Because the MTT assay does not provide insight into the 
molecular mechanisms involved in TRPV1 responses, addi-
tional research is needed to elucidate breast cancer cell viabil-
ity upon TRPV1 agonist and antagonist stimulation. Conse-
quently, the present data should be considered preliminary, 
although they do indicate that TRPV1 ligands may have po-
tential for anticancer drugs. Considerable effort has been 
made to fight cancer cells, and targeted therapy seems to be a 
promising strategy; in this regard, ion channels belonging to 
the TRP channel superfamily could play an important role 
[29]. Considering these findings, studies on TRPV1-mediated 
effects on human breast cancer cells should be encouraged. 
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